Turkish Journal of Physical Medicine and Rehabilitation 2008 , Vol 54 , Num 1

The effect of Raloxifene, Alendronate and Risedronate on Serum Lipid Profile in Postmenopausal Wome

Burcu Yanık 1 ,Duygu Geler Külcü 2
1 Fatih Üniversitesi Tıp Fakültesi, Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı, Ankara
2 Haydarpaşa Numune Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, İstanbul, Türkiye

Objective: To investigate the effect of raloxifene 60 mg/day, alendronate 70 mg/week and risedronate 35 mg/week on serum total cholesterol (TOT-C) (mg/dl) and triglycerides (TG) (mg/dl) during a 12 month treatment period.


Material and Methods:  Bone mineral density (BMD) of L2-L4 and femoral neck were evaluated in 127 patients who attended the Physical Medicine and Rehabilitation outpatient clinic. Age, menopause age, height, weight, cigarette and alcohol use were recorded. Patients were randomized into three groups. The first group (raloxifene) had 36, second group (alendronate) had 47 and third group (risedronate) had 44 patients (mean ages: 62±7, 62.6±8, 63.6±6 years, respectively). All groups received 1200 mg calcium and 800 IU vitamin-D  daily in addition to their drugs. Serum TOT-C and TG were evaluated at the beginning and after one year. 


Results: No serious adverse effects were seen in any of the groups. There were no differences between the groups regarding demographic features, L2-L4 and femur BMD levels. Serum TOT-C levels were slightly high and serum TG levels were within the normal range in all groups and did not differ within and between groups after one year follow-up. 


Conclusion: Raloxifene, alendronate and risedronate, which were used for the treatment of postmenopausal osteoporosis, did not affect serum TOT-C and TG levels during 12 month treatment period. 

Keywords : Postmenopausal osteoporosis, cholesterol, triglyceride, risedronate, alendronate, raloxifene